Menu
Search
|

Menu

Close
X

WAVE Life Sciences Ltd WVE.OQ (NASDAQ Stock Exchange Global Market)

26.56 USD
+2.62 (+10.94%)
As of 5:04 PM BST
Previous Close 23.94
Open 24.02
Volume 38,795
3m Avg Volume 87,303
Today’s High 26.74
Today’s Low 24.02
52 Week High 56.00
52 Week Low 18.16
Shares Outstanding (mil) 34.26
Market Capitalization (mil) 663.02
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY19
3
FY18
14
FY17
4
FY16
1
EPS (USD)
FY19
-1.356
FY18
-5.062
FY17
-3.836
FY16
-2.407
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
35.33
7.90
Price to Book (MRQ)
vs sector
4.14
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
--
17.64
LT Debt to Equity (MRQ)
vs sector
--
12.61
Return on Investment (TTM)
vs sector
-56.58
12.69
Return on Equity (TTM)
vs sector
-107.95
17.13

EXECUTIVE LEADERSHIP

Christian Henry
Independent Chairman of the Board, Since 2017
Salary: $94,902.00
Bonus: --
Paul Bolno
President, Chief Executive Officer, Director, Since 2013
Salary: $541,100.00
Bonus: --
Keith Regnante
Chief Financial Officer, Since 2016
Salary: $350,000.00
Bonus: --
Christopher Francis
Senior Vice President, Corporate Development, Head of Emerging Areas, Since 2017
Salary: $363,000.00
Bonus: --
Chandra Vargeese
Senior Vice President, Head of Drug Discovery, Since 2014
Salary: $400,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7 Straits View #12-00,
Marina One East Tower
    018936

Phone:

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington's disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.

SPONSORED STORIES